Dutch Startup Raises €1.7 Million to Bring Hospital-Grade Heart Testing to Your Living Room
Netherlands, Friday, 27 March 2026.
HeartEye’s breakthrough technology could revolutionize cardiac care by making professional 12-channel ECG recordings possible anywhere in under one minute. The funding from ROM InWest and tech industry veterans will accelerate market introduction of their wireless device, which enables general practitioners and nurses to perform hospital-quality heart diagnostics outside traditional medical settings. This innovation addresses a critical healthcare gap, as recent studies show AI-based ECG interpretation outperforms standard diagnosis methods with 99% specificity in detecting heart attacks. The portable solution promises earlier detection of heart conditions while reducing unnecessary hospital referrals, potentially saving lives and healthcare costs through more efficient cardiac monitoring accessibility.
Building on Strategic Investment Foundation
This funding round represents the latest development in ROM InWest’s strategic approach to bridging the notorious ‘Valley of Death’ for healthcare startups, as previously reported in our coverage of the regional investment agency’s life sciences portfolio (https://inspirega.bytes.news/e954f5b-life-sciences-investment-biotech-funding/). HeartEye’s €1.675 million capital injection, announced on March 27, 2026, exemplifies how targeted regional investment can accelerate promising healthtech innovations through critical regulatory phases [1]. The Dutch startup joins other ROM InWest portfolio companies addressing significant healthcare challenges, with infection treatment costs alone reaching €35 million annually in hospitals [GPT].
Revolutionary Technology Makes Hospital-Grade Diagnostics Portable
HeartEye’s patented mobile 12-channel ECG recorder transforms what has traditionally been a time-consuming and complex hospital procedure requiring trained professionals into a simple, one-minute process that can be performed anywhere [1]. The fully wireless device enables general practitioners, assistants, and nurses to conduct hospital-quality cardiac diagnostics outside traditional medical settings, with the capability for patients to eventually perform these tests at home [1]. The innovation addresses a critical gap in healthcare accessibility, particularly relevant given recent research demonstrating that AI-based ECG interpretation achieved 84% accuracy in correctly identifying obstructive myocardial infarction, compared to only 42% accuracy from human ECG interpretation [2].
Investor Confidence Reflects Market Potential
The investment round attracted notable technology industry veterans, including Schuberg Philis co-founder Pim Berger and Mphasis co-founder Jeroen Tas, alongside returning investor Health Innovations [1]. ROM InWest’s participation reflects the agency’s commitment to supporting MedTech innovations through the capital-intensive certification phase required under current Medical Device Regulation (MDR) standards [1]. This period represents a particularly challenging phase for healthcare startups, where significant investments must be made while regulatory compliance prevents clinical use and revenue generation [1].
Strategic Development and Market Introduction Timeline
The €1.675 million funding will support HeartEye’s pivotal clinical study execution and continued development of its AI software platform [1]. The company plans to advance its digital care platform while establishing production capacity to meet anticipated demand following market authorization [1]. ROM InWest anticipates that HeartEye’s innovation will contribute directly to sustainable and affordable healthcare delivery, positioning the company to become a leading player that stimulates high-quality employment and knowledge development in the region [1]. The timing proves particularly strategic, as the broader healthcare industry increasingly embraces AI-powered diagnostic tools, with recent studies showing 99% specificity and 98% negative predictive value for AI-based cardiac assessment [2].